Here are the pharma companies accused of blocking generic competition

To prove a generic drug is as safe and effective as the branded version, pharmaceutical companies have to hand over upwards of 1,000 doses of the product to a generic developer.
But if the manufacturer creating the generic drug cannot get its hands on enough sample, the development and testing process slows down. It could potentially even keep a generic version of the drug from ever reaching the market.
If companies developing generics have trouble accessing the samples they need, they can file a complaint with the FDA. Today, the FDA published a list of 39 pharmaceutical companies that have been the subjects of such complaints.
Get the full story at our sister site, Drug Delivery Business News.
The post Here are the pharma companies accused of blocking generic competition appeared first on MassDevice.

Source: Mass Device - May 17, 2018 Category: Medical Devices Authors: Sarah Faulkner Tags: Pharmaceuticals Regulatory/Compliance Wall Street Beat Actelion Celgene FDA Gilead Sciences GlaxoSmithKline plc johnsonandjohnson Novartis Valeant Pharmaceuticals Source Type: news